Delisting risk
iTonic (ITOC)
Treatment-planning software and medical supplies for radioactive-seed brachytherapy.
$0.3001
Pre-market−0.01 (−2.88%)
At close$0.3090(+5.86%)
In millions of USD, except per-share figures
| In millions | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general & administrative | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Operating income | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |
| Net income | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |
| EPS, basic | $0.00 | $0.00 | −$0.01 | −$0.01 | −$0.02 | −$0.03 | −$0.14 | −$0.18 |
| EPS, diluted | $0.00 | $0.00 | −$0.01 | −$0.01 | −$0.02 | −$0.03 | −$0.14 | −$0.18 |
| Weighted average shares, basic | 15 | 15 | 15 | 15 | 15 | 14 | 15 | 17 |
| Weighted average shares, diluted | 15 | 15 | 15 | 15 | 15 | 14 | 15 | 17 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | −2 | −3 |